Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Gilead Sciences is the lead sponsor of 67 current clinical trials in our USA, UK, China, India, Ireland and EU (CTIS) registers. 21 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Lenacapavir, Sacituzumab Govitecan and Carboplatin. The most-studied condition is HIV-1-infection.

Company profiles on this site (news, sites, medicines, approvals): Gilead Sciences (US) →Gilead Sciences (IE) →

ClinicalTrials.gov trials by status

Recruiting2134%
Active, closed4166%

Trials by phase

Phase 22032%
Phase 31931%
Phase 11321%
Phase 2/3711%
Phase 1/223%
Observational12%

Clinical trials sponsored by Gilead Sciences

62 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy NCT07682961 · HIV Infections Drugs: Cabotegravir, Lenacapavir, Rilpivirine	Phase 3	Recruiting	2026-07	USA
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) NCT05633654 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer Drugs: Capecitabine, Pembrolizumab, Sacituzumab Govitecan	Phase 3	Recruiting	2022-12	Ireland, UK, USA
A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors NCT07703878 · Solid Tumor	Phase 1	Recruiting	2026-07	USA
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas NCT07546812 · HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma Drugs: Denikitug, Nivolumab, Paclitaxel	Phase 2	Recruiting	2026-08	USA
Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment NCT07708727 · HIV-1-infection Drugs: B/F/TAF, GS-3242, Lenacapavir	Phase 2/3	Recruiting	2026-07	USA
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis NCT06051617 · ClinicalTrials.gov ↗ · Primary Biliary Cholangitis Drug: Seladelpar	Phase 3	Recruiting	2023-09	UK, USA, China
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer NCT06801834 · ClinicalTrials.gov ↗ · Extensive Stage Small Cell Lung Cancer (ES-SCLC) Drugs: Amrubicin, Lurbinectedin, Sacituzumab Govitecan	Phase 3	Recruiting	2025-04	UK, USA, China
Study of GS-2426 in Participants With Advanced Solid Tumors NCT07601243 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	2026-06	USA
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention NCT07473778 · ClinicalTrials.gov ↗ · HIV Infections Drugs: Cabotegravir, Emtricitabine/tenofovir disoproxil fumarate, F/TAF	Observational	Recruiting	2026-03	USA
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment NCT04617522 · ClinicalTrials.gov ↗ · Advanced or Metastatic Solid Tumor, Liver Failure	Phase 1	Recruiting	2021-04	USA
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1 NCT07645287 · ClinicalTrials.gov ↗ · HIV-1-infection Drugs: B/F/TAF, GS-3242, Lenacapavir	Phase 2	Recruiting	2026-06	USA
Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens NCT07683000 · ClinicalTrials.gov ↗ · HIV-1-infection Drugs: Lenacapavir, Teropavimab, Zinlirvimab	Phase 3	Recruiting	2026-07	USA
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors NCT06167317 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drug: Sacituzumab Govitecan	Phase 1	Recruiting	2024-01	USA
Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus NCT07096193 · ClinicalTrials.gov ↗ · Chronic Hepatitis Delta	Phase 1/2	Recruiting	2025-07	USA
Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors NCT07128303 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Drugs: Carboplatin, Pembrolizumab, Pemetrexed	Phase 1	Recruiting	2025-08	USA
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM) NCT06562907 · ClinicalTrials.gov ↗ · Weight Management Drug: Omeprazole	Phase 1	Recruiting	2024-08	USA
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer NCT07527858 · ClinicalTrials.gov ↗ · Advanced Microsatellite Stable Colorectal Cancer Drugs: Bevacizumab, Denikitug, Nivolumab	Phase 2	Recruiting	2026-05	USA
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer NCT06926920 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer Drug: Sacituzumab Govitecan	Phase 1/2	Recruiting	2025-04	USA
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors NCT06532565 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drug: Zimberelimab	Phase 1	Recruiting	2024-07	USA
Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children NCT06749054 · ClinicalTrials.gov ↗ · HIV-1-infection Drug: Lenacapavir	Phase 2	Recruiting	2025-03	USA
Study of GS-0415 and How It Works in People With HIV NCT07719491 · ClinicalTrials.gov ↗ · HIV -1 Infection	Phase 1	Recruiting	2026-07	USA
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors NCT03964727 · Metastatic Solid Tumor Drug: Sacituzumab Govitecan	Phase 2	Active, closed	2019-10	USA
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread NCT03547973 · Metastatic Urothelial Cancer Drugs: Avelumab, Carboplatin, Cisplatin	Phase 2	Active, closed	2018-08	UK, USA
Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP) NCT07047716 · HIV Pre-exposure Prophylaxis Drug: Lenacapavir	Phase 3	Active, closed	2025-07	USA
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer NCT05502237 · Non-small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Domvanalimab	Phase 3	Active, closed	2022-10	UK, USA, China
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer NCT05382286 · Triple Negative Breast Cancer, PD-L1 Positive Drugs: Carboplatin, Gemcitabine, Nab-paclitaxel	Phase 3	Active, closed	2022-07	UK, USA
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy NCT06333808 · HIV-1-infection Drugs: B/F/TAF, Bictegravir, Lenacapavir	Phase 3	Active, closed	2024-03	UK, USA
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer NCT05382299 · Triple Negative Breast Cancer, PD-L1 Negative Drugs: Carboplatin, Gemcitabine, Nab-paclitaxel	Phase 3	Active, closed	2022-07	UK, USA, China
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 NCT06727565 · Head and Neck Squamous Cell Carcinoma Drugs: Carboplatin, Domvanalimab, Paclitaxel	Phase 2	Active, closed	2025-02	UK, USA, China
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1 NCT06630286 · HIV-1-infection Drugs: B/F/TAF, ISL/LEN	Phase 3	Active, closed	2024-10	UK, USA
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection NCT02932150 · ClinicalTrials.gov ↗ · Chronic Hepatitis B	Phase 2	Active, closed	2016-11	USA, India
Study With Various Immunotherapy Treatments in Participants With Lung Cancer NCT05676931 · ClinicalTrials.gov ↗ · Advanced Non-Small Cell Lung Cancer Drugs: Docetaxel, Domvanalimab, Quemliclustat	Phase 2	Active, closed	2023-02	UK, USA
Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection NCT01651403 · ClinicalTrials.gov ↗ · Chronic Hepatitis B	Phase 3	Active, closed	2012-12	USA, India
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis NCT06029972 · ClinicalTrials.gov ↗ · Ulcerative Colitis	Phase 2	Active, closed	2023-12	UK, USA
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen NCT05502341 · ClinicalTrials.gov ↗ · HIV-1-infection Drugs: BIC/LEN FDC, Bictegravir, Lenacapavir	Phase 2/3	Active, closed	2022-08	UK, USA
Study of Novel Treatment Combinations in Patients With Lung Cancer NCT05633667 · ClinicalTrials.gov ↗ · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Docetaxel	Phase 2	Active, closed	2023-03	UK, USA
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy NCT05840211 · ClinicalTrials.gov ↗ · Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Drugs: Capecitabine, Nab-paclitaxel, Paclitaxel	Phase 3	Active, closed	2023-05	UK, USA, China
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV NCT07055451 · HIV-1-infection Drug: B/F/TAF	Phase 1	Active, closed	2025-08	USA
Study of GS-4528 in Adults With Solid Tumors NCT05840224 · ClinicalTrials.gov ↗ · Solid Tumor Drug: Zimberelimab	Phase 1	Active, closed	2023-05	UK, USA
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV NCT02016924 · ClinicalTrials.gov ↗ · Acquired Immune Deficiency Syndrome (AIDS), HIV Infections Drugs: Cobicistat, F/TAF, LPV/r	Phase 2/3	Active, closed	2014-01	UK, USA
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) NCT05089734 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drugs: Docetaxel, Sacituzumab Govitecan	Phase 3	Active, closed	2021-11	UK, USA
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) NCT05186974 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Paraplatin	Phase 2	Active, closed	2022-05	UK, USA
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 NCT06630299 · ClinicalTrials.gov ↗ · HIV-1-Infection Drug: ISL/LEN	Phase 3	Active, closed	2024-10	UK, USA
Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 NCT06532656 · HIV-1-infection Drugs: BIC/LEN FDC, Lenacapavir	Phase 2/3	Active, closed	2024-11	USA
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) NCT06486441 · ClinicalTrials.gov ↗ · Endometrial Cancer Drugs: Doxorubicin, Paclitaxel, Sacituzumab Govitecan	Phase 3	Active, closed	2024-08	UK, USA, China
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1 NCT02881320 · ClinicalTrials.gov ↗ · HIV-1 Infection Drug: B/F/TAF	Phase 2/3	Active, closed	2016-09	USA
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC) NCT03301506 · ClinicalTrials.gov ↗ · Primary Biliary Cirrhosis Drug: Seladelpar	Phase 3	Active, closed	2017-12	UK, USA
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis NCT06290934 · ClinicalTrials.gov ↗ · Ulcerative Colitis	Phase 2	Active, closed	2024-03	UK, USA, China
Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP) NCT06513312 · ClinicalTrials.gov ↗ · Pre-Exposure Prophylaxis of HIV Infection Drugs: Emtricitabine/tenofovir disoproxil fumarate, F/TDF, Lenacapavir	Phase 2	Active, closed	2024-10	UK
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors NCT05007782 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Drugs: Denikitug, Zimberelimab	Phase 1	Active, closed	2021-08	USA
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103) NCT06101342 · ClinicalTrials.gov ↗ · Pre-Exposure Prophylaxis of HIV Infection Drugs: Emtricitabine/tenofovir disoproxil fumarate, F/TDF, Lenacapavir	Phase 2	Active, closed	2023-12	USA
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection NCT05729568 · ClinicalTrials.gov ↗ · HIV-1 Infection Drugs: Lenacapavir, Teropavimab, Zinlirvimab	Phase 2	Active, closed	2023-05	USA
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance NCT04150068 · ClinicalTrials.gov ↗ · HIV-1-infection Drug: Lenacapavir	Phase 2/3	Active, closed	2019-11	USA
Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV NCT05052996 · ClinicalTrials.gov ↗ · HIV-1 Infection Drug: B/F/TAF	Phase 2	Active, closed	2021-10	USA
Study of GS-0151 in Participants With Rheumatoid Arthritis NCT06902519 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis	Phase 1	Active, closed	2025-05	USA
Study of Sacituzumab Govitecan in Patients With Solid Tumor NCT05119907 · ClinicalTrials.gov ↗ · Solid Tumor Drug: Sacituzumab Govitecan	Phase 2	Active, closed	2021-10	China
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102) NCT06101329 · ClinicalTrials.gov ↗ · Pre-Exposure Prophylaxis of HIV Infection Drugs: Emtricitabine/tenofovir disoproxil fumarate, F/TDF, Lenacapavir	Phase 2	Active, closed	2023-11	USA
Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection NCT04925752 · ClinicalTrials.gov ↗ · Pre-Exposure Prophylaxis of HIV Infection Drugs: F/TAF, F/TDF, Lenacapavir	Phase 3	Active, closed	2021-06	USA
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors NCT06082960 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 1	Active, closed	2023-10	USA
Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed NCT06544733 · ClinicalTrials.gov ↗ · HIV-1-Infection	Phase 2/3	Active, closed	2024-08	USA
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) NCT04639986 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer Drugs: Eribulin mesylate, Gemcitabine, Sacituzumab Govitecan	Phase 3	Active, closed	2020-11	China
Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments NCT04454437 · ClinicalTrials.gov ↗ · Metastatic Triple-negative Breast Cancer Drug: Sacituzumab Govitecan	Phase 2	Active, closed	2020-10	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Gilead Sciences in the EU trials register (CTIS)

5 trials

Authorised or ongoing trials in the EU Clinical Trials Information System with Gilead Sciences as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
Study of GS-2426 in Participants With Advanced Solid Tumors 2026-526264-20-00 · Neoplasms	Phase 1	Authorised	Spain
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice Yearly in Virologically Suppressed Adults with HIV-1 Infection on Stable Oral Treatment Regimens 2025-524336-19-00 · Virus Diseases Drugs: Efavirenz, Lamivudine, Lenacapavir	Phase 3	Ongoing	Poland, Italy, France + 3 more
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy 2025-524335-39-00 · Virus Diseases Drugs: Cabotegravir, Lenacapavir, Rilpivirine	Phase 3	Ongoing	Netherlands, Poland, Germany + 3 more
A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC). 2025-523984-39-00 · CTIS ↗ · Neoplasms Drugs: Bevacizumab, Denikitug, Nivolumab	Phase 2	Authorised	Spain, Italy, France
Study of GS-5319 in Adults With Solid Tumors 2025-522397-36-00 · CTIS ↗ · Neoplasms	Phase 1	Ongoing	Spain

Drugs in Gilead Sciences trials

50 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 10 more in the trial list above.

Conditions in Gilead Sciences trials

44 conditions

HIV-1-infection10 Triple Negative Breast Cancer4Pre-Exposure Prophylaxis of HIV Infection4Solid Tumor3 HIV Infections3 HIV-1 Infection3 Advanced Solid Tumors3 Non-small Cell Lung Cancer2 Ulcerative Colitis2 HIV-1-Infection2 Advanced Solid Tumor2 Chronic Hepatitis B2Metastatic Urothelial Cancer1PD-L1 Positive1PD-L1 Negative1Head and Neck Squamous Cell Carcinoma1 Advanced Non-Small Cell Lung Cancer1 Lung Cancer1Advanced or Metastatic Non-Small-Cell Lung Cancer1Resectable Non-Small-Cell Lung Cancer1Locally Advanced or Unresectable Metastatic Breast Cancer1Stage IV Breast Cancer1Primary Biliary Cholangitis1Acquired Immune Deficiency Syndrome (AIDS)1

By trial register

Register	Trials	Recruiting
Clinical trials in USA	58	21
Clinical trials in UK	24	3
Clinical trials in China	11	2
Clinical trials in India	2	0
Clinical trials in Ireland	1	1
EU register (CTIS)	5	—

A trial with sites in more than one country appears in each of those registers.

Questions about Gilead Sciences trials

How many clinical trials does Gilead Sciences sponsor?

Gilead Sciences is the lead sponsor of 62 current trials on ClinicalTrials.gov in our USA, UK, China, India and Ireland registers, and 5 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Gilead Sciences trials recruiting?

Yes. 21 of its 62 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Gilead Sciences testing?

Its current trials name 50 drugs and biologicals as interventions. The most frequent are Lenacapavir (18), Sacituzumab Govitecan (16), Carboplatin (8), Paclitaxel (8) and Zimberelimab (8). The number in brackets is how many of its trials name each drug.

Does Gilead Sciences have clinical trials in Ireland?

Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Gilead Sciences clinical trials